Cuba to Produce Therapeutic Vaccines against Lung Cancer

Havana, Jan 12 (Prensa Latina) Cuba will install new plants for the production of a vaccine against lung cancer, guaranteeing the continuation of clinic trials and start similar effective tests in United States.

The assembly of three new plants will take place within six months to produce a therapeutic vaccine against lung cancer, according to Trabajadores local weekly.

Dr. Gisela González, who leads the project in the Molecular Immunology Center (CIM) told press that her center is assembling one plant and the Genetic Immunology Center two.

The Genetic and Biotechnology Immunology Center will produce the active ingredients of the EGF-P64K vaccine and the Molecular Immunology Center will make the final product, said Dr. González who has been working on this project for two years.

The plants will comply with the requirements demanded by United States to allow the clinical trials. The requirements are part of an agreement signed in 2004 by CIM and the US firm CANCERVAX, one of the main companies researching vaccines in the world.

The CIM is currently working on two research projects against cancer. One is the stimulus of the immunology system with vaccines that produce antibodies against the disease. The other is the use of monoclonal antibodies to prevent the development of tumors, the CIM expert said.

Best viewed with Internet Explorer browser
800 x 600 resolution
Copyright © Ministry of Foreign Affairs, Republic of Cuba, 2003